Verve pauses lead base editing program after safety event, switches focus to follow-up candidate near clinic
Verve Therapeutics is pausing work on its lead gene editing treatment, which was the first time base editing was used to directly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
